SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is trending due to positive news regarding its APU CIM architecture achieving GPU-class AI performance with significantly lower energy consumption, sparking community discussion about potential buyouts and comparisons to other AI and chip companies like NVDA. The community is actively debating whether the stock is primed for a short squeeze and discussing strategies to capture further upside. Some traders express concerns about potential dilution and the company's history, while others focus on the potential for long-term growth in the AI and edge computing sectors.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as users report widespread platform outages, potentially linked to Amazon Web Services, sparking frustration and concerns about accessibility during trading. The community is debating the cause of the issues, with some questioning the reliability of the platform and others attributing it to broader internet service disruptions. Despite the technical difficulties, the stock price has shown surprising resilience, leading to discussions about market dynamics and potential manipulation.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

REPL is trending due to news of FDA acceptance of its Biologics License Application resubmission, sparking optimism and driving discussions around potential price targets. Community members are actively debating the company's future prospects, with some highlighting new price targets and potential breakouts, while others express skepticism and point to potential shorting opportunities. The stock's collaborations and setup are also being closely watched by traders.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending as investors discuss the implications of new data, with some citing a strong response rate in lung cancer patients from a GenFleet study. While some view the sell-off as an overreaction or manipulation, others question the long-term impact and management's spending. The community is actively debating the data's significance and comparing it to competitors in the KRAS G12D space.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as analysts debate the achievability of its ambitious long-term growth targets outlined during its Analyst Day, specifically regarding revenue and AI infrastructure spending. The community is actively discussing whether AI infrastructure investments will impact profitability, and some are drawing comparisons to past optimistic guidance from the company. Overall, sentiment appears mixed as investors weigh the potential for future growth against possible short-term financial strain.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as the company explores rare earth mineral production, potentially transforming it into a strategic metals player amid tightening export controls from China. This pivot is sparking discussions about the company's growth potential beyond steel, with some seeing it as a smart move while others question execution and debt. Community members are closely monitoring its Q3 earnings report to determine if it can meet expectations.

FLOKI is the utility token of the Floki Ecosystem. The Floki Ecosystem is a community-powered ecosystem that aims to give people control of their finances through four key utility offerings:  - The Valhalla NFT Metaverse Game. - The Floki University Crypto Education platform. - DeFi. - The FlokiPlaces NFT & Merchandise Marketplace.

Floki Token

Floki is trending due to its recent listing on Robinhood, generating excitement within the community; many anticipate a significant price surge following the listing. Community members are drawing comparisons to Dogecoin and Shiba Inu, while others are focused on long-term price predictions and utility.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as the stock flirts with all-time highs, driven by positive sentiment around iPhone 17 sales and potential AI integration. Community discussions revolve around analyst upgrades, revenue projections, and the ongoing battle for AI talent with companies like Meta. Some investors express concerns about valuation and potential market corrections, while others remain bullish, anticipating a continued rally.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending due to a significant AWS outage impacting numerous websites and services, sparking concerns about the company's reliability and the internet's dependency on its cloud infrastructure. While some traders anticipate a dip due to potential customer refunds and reputational damage, others see the event as a reminder of AWS's central role in the digital economy, viewing it as a buying opportunity. Community discussions revolve around the outage's impact on various sectors and whether it will affect Amazon's upcoming earnings.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

CELC is trending due to positive Phase 3 trial results for its breast cancer therapy, leading to analysts raising price targets and optimism for FDA approval. The community is actively discussing the potential for a buyout and the stock's strong institutional ownership, while some caution against hype and potential dilutions. Attention is also focused on the company's upcoming data releases and potential for market dominance in its sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>FDA has accepted Replimune’s RP1 resubmission for advanced melanoma treatment.</li><li>Prescription Drug User Fee Act decision date is set for April 10, 2026.</li><li>Wedbush raised its rating on Replimune to ‘Outperform’ from ‘Neutral’ and increased its price target to $18 from $4.</li></ul>Replimune Group Inc.(REPL) on Monday announced that it has cleared a major regulatory hurdle after the U.S. Food and Drug Administration (FDA) accepted its resubmitted Biologics License Application (BLA) for RP1, a treatment for advanced melanoma.The FDA has set April 10, 2026, as the Prescription Drug User Fee Act (PDUFA) target action date for this Class II resubmission.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/REPL">Replimune stock</a>&nbsp;traded over 98% higher on Monday morning and was the third most trending equity ticker on Stocktwits. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day while message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">What Is RP1?</h2>RP1 is Replimune’s lead therapy candidate. It is derived from a modified herpes simplex virus, engineered to enhance tumor cell destruction and stimulate the body’s immune system against cancer. The therapy is designed with a fusogenic protein (GALV-GP R-) and GM-CSF to amplify both tumor-killing activity and the immune response.<blockquote>“RP1 plus nivolumab offers a strong risk benefit profile where there are few options for patients with advanced melanoma, who have progressed on PD-1 based therapy."- Sushil Patel, CEO, Replimune.</blockquote>The BLA resubmission follows several months of engagement between the company and the agency. Replimune worked to incorporate additional clinical data, detailed analyses and supporting documentation to address regulatory concerns.<h2 class="st-heading-2">What Are Analysts Saying?</h2>Wedbush raised its rating on Replimune to ‘Outperform’ from ‘Neutral’ and increased its price target to $18 from $4, according to TheFly. The firm sees the FDA’s quick response after a Type A meeting as an encouraging sign, suggesting the agency is open to the updated application with the new data included.Leerink analyst Jonathan Chang raised the firm’s rating to ‘Outperform’ from ‘Market Perform’ and lifted the price target to $13 from $3, expressing renewed confidence in RP1.&nbsp;Replimune stock has lost over 14% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sealsq-stock-jumps-13-today-company-s-first-chip-with-built-in-post-quantum-encryption-draws-attention/ch6CDEMR3Yn">SEALSQ Stock Jumps 13% Today: Company’s First Chip With Built-In Post-Quantum Encryption Draws Attention</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

What Is Driving Replimune Stock’s 98% Surge Today? 

FDA has accepted Replimune’s RP1 resubmission for advanced melanoma treatment.

Equity

REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug

Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.

Replimune Group, Inc. (REPL) announced on Thursday that a path forward for approval of its lead candidate for the treatment of advanced melanoma has not been determined, despite a meeting with the U.S. Food and Drug Administration. Shares of the company slumped 42% at the time of writing.The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. The agency said in the letter that it is unable to approve the application in its present form and indicated that the trial conducted by the company for the drug is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.The company subsequently requested a meeting with the agency to push for approval of RP1. “We remain steadfastly committed to patient access while we work with the FDA to secure regulatory approval for RP1, however, without accelerated approval based on the current application, continuation of the RP1 program in advanced melanoma, including the phase 3 confirmatory trial, will not be viable,” CEO Sushil Patel said earlier this month.However, on Thursday, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.replimune.com/news-releases/news-release-details/replimune-provides-update-following-type-meeting-fda">stated</a> that it had completed a meeting with the FDA on September 16 regarding the letter pertaining to the application for approval of RP1. The company stated that it is evaluating the feedback from the FDA to determine its next steps, and the path forward under the accelerated approval pathway has not yet been determined.“We remain committed to working with the FDA to determine an expeditious path forward for RP1,” Patel reiterated on Thursday.RP1 is Replimune’s lead product candidate. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">REPL stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:571/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_18_at_11_25_42_AM_png_83a21ea942.webp" alt="REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits" width="571" height="64"><figcaption>REPL's Sentiment Meter and Message Volume as of 11:26 a.m. ET on Sept. 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that a strategic review announcement is due in the coming months.<stembedurl>https://stocktwits.com/Bakhmutbull2/message/629140552</stembedurl>A more optimistic user, however, said that RP1 remains “a therapy to watch” for melanoma patients.<stembedurl>https://stocktwits.com/sousayuri/message/629114614</stembedurl>REPL stock is down by about 73% this year and by about 70% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ge-healthcare-reportedly-eyes-selling-stake-in-china-unit/chDcxTmR3bI">GE Healthcare Reportedly Eyes Selling Stake In China Unit – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Replimune Stock Plunged 42% Today – Here’s Why

The company stated that it is evaluating feedback from the FDA regarding the approval of its lead candidate for the treatment of advanced melanoma to determine its next course of action. 

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit - REPL Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of...

Retail&nbsp;trader buzz around Replimune Group surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ‘Neutral’, citing the sudden resignation of Vinay Prasad, former head of the FDA’s biologics division, as a key development that could improve the outlook for RP1, the company’s lead oncolytic immunotherapy candidate.The stock more than doubled Wednesday, closing up 101% at $7.55.Cantor analyst Li Watsek said the FDA’s Complete Response Letter (CRL) issued on July 22 for RP1 in combination with nivolumab was likely influenced by senior leadership, possibly Prasad, overruling the agency’s review team.&nbsp;Watsek sees Prasad’s exit as “removing a major obstacle” and believes the odds of RP1 receiving accelerated approval have “greatly improved.” Cantor expects Replimune shares could return to pre-CRL levels above $12 if the decision is overturned.BMO Capital analyst Evan Seigerman&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/replimune-sarepta-capricor-stocks-surge-after-vinay-prasad-fda-exit/choXJLOR5Cg">also said</a> Prasad’s departure is a net positive for the biopharma sector, noting that a new FDA biologics director is “likely to be more permissive of innovation.” While BMO remains uncertain whether RP1 will be reconsidered, the firm expects shares to rally meaningfully on the change.<a href="https://stocktwits.com/news-articles/markets/equity/fda-official-who-halted-sarepta-s-gene-therapy-resigns-amid-backlash-over-access-to-duchenne-treatment/choQYmjR5yz">Prasad stepped down</a> just two months into his role leading the FDA’s biologics division, after facing growing backlash over how he handled Sarepta’s Elevidys, the only approved gene therapy for Duchenne muscular dystrophy.Earlier this month, Prasad and FDA Commissioner Marty Makary asked Sarepta to halt shipments of Elevidys after three children who received the therapy died, including two from liver failure.&nbsp;The move ignited backlash from patient advocates and conservative media, who slammed the agency for standing in the way of what many families see as a last hope for kids battling a fatal condition.&nbsp;Replimune stated that the CRL for RP1 cited the Ignyte Phase 1/2 trial as lacking the rigor to support approval, due to heterogeneity in the patient population and concerns regarding the confirmatory study design. No safety issues were raised.&nbsp;The company plans to request a Type A meeting with the FDA to explore a path forward for accelerated approval.CEO Sushil Patel expressed surprise at the CRL, noting that the issues raised&nbsp;had not been&nbsp;discussed during the mid- and late-cycle reviews. RP1, engineered from a herpes simplex virus, is designed to directly kill tumors and trigger a systemic immune response.&nbsp;It’s the lead program in Replimune’s proprietary RPx platform, which the company believes can work&nbsp;independently or&nbsp;in conjunction with other cancer therapies.On Stocktwits, retail sentiment for Replimune was ‘extremely bullish’ late Wednesday amid a 1,038% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/REPL">Replimune’s stock</a> has declined nearly 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail buzz around Replimune Group (REPL) surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ‘Neutral.’ (Photo credit: Getty Images)

Replimune Stock Catches Retail Fire As Analyst Says FDA Shakeup Removes 'Major Obstacle' For Skin Cancer Drug's Potential Approval

Analysts believe the resignation of a top FDA official could lead to a reversal of the melanoma drug rejection, which was based on trial design concerns.

Shares of Replimune Group Inc. (REPL) were in the retail spotlight on Wednesday after the stock nearly doubled in value.BMO Capital expects the stock to witness a meaningful rally following the exit of Vinay Prasad from the U.S. Food and Drug Administration, according to TheFly. Prasad stepped down as Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.Meanwhile, shares of Capricor Therapeutics (CAPR) and Sarepta Therapeutics (SRPT) clocked moderate gains.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REPL">Replimune</a> jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1244/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_30_at_12_32_01_PM_png_ac2aea7c7b.webp" alt="REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits" width="1244" height="130"><figcaption>REPL's Sentiment Meter and Message Volume as of 12:30 p.m. ET on July 30, 2025 | Source: Stocktwits</figcaption></figure>As per Stocktwits data, retail chatter around Replimune surged over 1500% over the past 24 hours.Prasad was appointed in May to replace Peter Marks, who was removed from CBER after conflicting with Health and Human Services Secretary Robert F. Kennedy Jr. over vaccine policy.BMO Capital analyst Evan Seigerman views the exit of Vinay Prasad as a positive for the biopharma sector. A new director will "likely be more permissive of innovation than what we have seen to date," the analyst told investors in a research note.BMO, however, remains uncertain on whether a new CBER director will reconsider the denial of approval to the company’s lead product candidate, RP1.Earlier this month, Replimune received a letter from the FDA indicating that it is unable to approve the company’s application for RP1 in combination with Nivolumab for the treatment of advanced melanoma.The agency deemed the trials cited by the company as not adequate to substantiate the effectiveness of the drug. The FDA also said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.The company then said it will request a meeting with the FDA as it plans to interact with the agency to find a path for approval. CEO Sushil Patel stated that the company is surprised and disappointed by the decision.Leerink, meanwhile, views the exit of Prasad as a positive for rare disease and genetic medicines, negative for vaccines, and unclear for oncology, as per TheFly. While Prasad restricted the use of COVID-19 vaccines during his tenure, Leerink expects the new chief to be more in alignment with Robert F. Kennedy Jr. and his anti-vaccine stance.Shares of <a href="https://stocktwits.com/symbol/CAPR">Capricor</a> Therapeutics also traded 25% higher on Wednesday. The FDA had earlier refused to approve its lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-names-former-gm-exec-to-lead-commercial-vehicle-segment/choXEl9R5C4">Ford Names Former GM Executive To Lead Commercial Vehicle Segment: Retail’s Skeptical Ahead Of Q2 Earnings Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

REPL Stock Nearly Doubled In Value Today: What's Going On?

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job. 

Replimune, Sarepta, Capricor Stocks Surge: Analyst Says Vinay Prasad’s Exit From FDA Positive For Biopharma Sector

Replimune, Inc. (<a class="mention" data-mention="$REPL" data-symbol-id="REPL" href="https://stocktwits.com/symbol/REPL" target="_blank">$REPL</a>) shares spiked higher in Thursday’s after-hours session after the small-cap biopharma developing oncolytic immunotherapies, provided a key regulatory update for its combo therapy candidate to treat skin cancer, lifting retail sentiment.The Woburn, Mass.-based clinical-stage biopharma said after the market closed that it has submitted a biologic license application (BLA) for RP1, aka vusolimogene oderparepvec, -&nbsp; its lead immulytic product candidate, in combination with Bristol-Myers Squibb Co.’s (<a class="mention" data-mention="$BMY" data-symbol-id="BMY" href="https://stocktwits.com/symbol/BMY" target="_blank">$BMY</a>) Opdivo, for advanced melanoma patients who have been previously treated with anti-PD1 therapies.Anti-PD1 therapy is currently the standard of care for several types of cancer.RP1 is based on a proprietary new strain of the Herpes simplex virus engineered to maximize tumor killing potency, the immunogenicity of tumor cell death and the activation of a systemic anti-tumor immune response.The regulatory filing has been done under the accelerated approval pathway, which expedites approval for drugs to treat unmet needs based on a “surrogate endpoint,” rather than a direct measure of clinical benefit.The combo therapy also received FDA’s breakthrough therapy designation (BTD) based on the safety and clinical activity observed in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.A BTD designation is meant to expedite drug development for treating life-threatening and serious medical conditions by allowing increased FDA interactions and intensive guidance from the agency.Sushil Patel, CEO of Replimune, said, "Today is an important milestone for Replimune and for the melanoma community as we are one step closer to having another potential treatment available for patients who have limited options after progressing on anti-PD1 containing regimens.”The biopharma said patients are&nbsp;currently being enrolled for the confirmatory late-stage study, dubbed IGNYTE-3 trial.<figure class="image"><a href="https://stocktwits.com/symbol/REPL"><img style="aspect-ratio:635/137;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/repl_sentiment_0c14327fe5.png" alt="repl-sentiment.png" width="635" height="137"></a><figcaption>REPL sentiment and message volume November 22, 2024, as of 3:25 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment inflected higher from ‘neutral’ (46/100) a day ago to ‘bullish’ (57/100), with message volume rising to ‘extremely high.’Replimune stock climbed 19.37% in Thursday’s after-hours session to $13.19, its highest level in a little over a year. The stock has gained 31.08% for the year-to-date period.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/reddit-stock-drops-on-insider-sales/cJI5NjxRXx">Reddit Stock Pulls Back From Record Highs After Tencent Cuts Stake Yet Again: Retail Turns Apprehensive</a>

Replimune's RP1+Opdivo combo therapy gets breakthrough therapy designation. 

Replimune Stock Hits 1-Year High In After-hours As Small-Cap Biotech Files For FDA Approval Of Skin Cancer Combo Therapy: Retail Upbeat

Replimune’s lead asset RP1 is based on a proprietary new strain of Herpes simplex virus engineered to maximize tumor killing potency.

Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patientsSAN DIEGO, April 07, 2024...

Replimune Group announces inducement grants under Nasdaq listing rule

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

REPL
Replimune Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest REPL News

REPLReplimune Group Inc